참고문헌
- Al-Moundhri M, Al-Bahrani B, Pervez I, et al (2004).The outcome of treatment of breast cancer in a developing country-oman. The Breast, 13, 139-45. https://doi.org/10.1016/j.breast.2003.10.001
- Arends L.R, Myriam Hunink M.G, Stijnen Th (2008).Metaanalysis of summary survival curve data. Statistics in Med, 27, 4381-96. https://doi.org/10.1002/sim.3311
- American Cancer Society (2010).Breast cancer facts & figures .Atlanta; American Cancer Society, Inc.
- Arkoob K, Al-Nsour M, Al-Nemry O, Al-Hajawi B (2010). Epidemiology of breast cancer in women in Jordan: patient characteristics and survival analysis. East Mediterr Hlth J, 16, 1032-8.
- Abbas H, Elyamany A, Salem M, et al (2011). The optimal sequence of radiotherapy and chemotherapy in adjuvant treatment of breast cancer. Int Arch Med, 4, 35-42. https://doi.org/10.1186/1755-7682-4-35
- Brunner, Suddarth's (2008). Textbook of medical-surgical nursing. 11th Edition, chapter 1.
- Dear KBG (1994). Iterative generalized least squares for metaanalysis of survival data at multiple times. Biometrics, 50, 989-1002. https://doi.org/10.2307/2533438
- Duolao W, Ameet B, Felicity C (2006). A Practical Guide to Design, Analysis, and Reporting Clinical Trials. London Remedica, chapter 38.
- Dersimonian R, Kacher R (2007). Random-effect model for meta-analysis of clinical trials: an update. Contemp Clinical Trials, 28, 105-14. https://doi.org/10.1016/j.cct.2006.04.004
- Di Leo A, Desmedt C, Bartlett J, et al (2011). HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol, 12, 1134-42. https://doi.org/10.1016/S1470-2045(11)70231-5
- Faradmal J, Kazemnejad A, Khoda BR, Hajizade E, Gohari MR (2010). Comparing three adjuvant chemotherapy regimens after modified radical mastectomy in breast cancer patients using log-logistic model. Sci J Semnan Univ Med Sci, 11, 279-86.
- Hedges LV, Vevea JL (1998). Fixed and random effects model in meta-analysis. Psychological Methods, 3, 486-504. https://doi.org/10.1037/1082-989X.3.4.486
- Ismaili N, Mellas N, Masbah O, et al (2009). Concurrent chemoradiotherapy in adjuvant treatment of breast cancer. Radiat Oncol, 4, 12-25. https://doi.org/10.1186/1748-717X-4-12
- Ismaili N, Elmajjaoui S, Lalya I, et al (2010). Anthracycline and concurrent radiotherapy as adjuvant treatment of operable breast cancer: a retrospective cohort study in a single institution. BMC Res Notes, 3, 247-57.
- Kleinbaum D (2004). Survival analysis a self- learning text. Springer.
- Kuru B, Camlibel M, Dine S, et al (2005). A comparison of the outcomes of non-randomized chemotherapy regimens in node positive breast cancer. J Exp Clin Cancer Res, 3, 363-71.
- Katalinic A, Pritzkuleit R, Waldmann A (2009). Recent trends in breast cancer incidence and mortality in Germany. Breast Care, 4, 75-80. https://doi.org/10.1159/000211526
- Kim K, Chie EK, Han W, et al (2011).Concurrent versus sequential administration of CMF chemotherapy and radiotherapy after breast-conserving surgery in early breast cancer. Tumori, 97, 280-5.
- Lian-Fang Li, Xiao-Jing Xu, Zhao Y, et al (2008). Integrated gene expression profile predicts prognosis of breast cancer patients. Breast Cancer Res Treat, 113, 231-7.
- Mousavi SM, Montazeri A, Mohagheghi MA, et al (2007). Breast cancer in iran: an epidemiological review. The Breast J, 13, 383-91. https://doi.org/10.1111/j.1524-4741.2007.00446.x
- Sakakibara M, Nagashima T, Kadowaki M, et al (2009). Clinical significance of axillary microresiduals after neoadjuvant chemotherapy in breast cancer patients with cytologically proven metastases. Ann Surg Oncol, 16, 2470-8. https://doi.org/10.1245/s10434-009-0612-4
- Wong ZW, Ang PCS (2008). Phase I/II study of gemcitabine with pegylated liposomal doxorubicin as first-line therapy in asian women with metastatic breast cancer. The Breast, 17, 517-22. https://doi.org/10.1016/j.breast.2008.03.009
- Wang SH, Yanxia S, Yuan ZH, et al (2011). Classical CMF regimen as adjuvant chemotherapy for triple-negative breast cancer may be more effective compared with anthracycline or taxane-based regimens. Med Oncol, 11, 9964-72.
- Yan PW, Huang XE (2010). Clinical comparison of safety and efficacy of vinorelbine/epirubicin (NE) with fluorouracil/epirubicin/ cyclophosphamide (FEC). Asian Pac J Cancer Prev, 11, 1115-8.
- Zhang J, Yan LIU (2008). HER2 over-expression and response to different chemotherapy regimens in breast cancer. J Zhejinang University Science, 9, 5-9. https://doi.org/10.1631/jzus.B073003
피인용 문헌
- High-throughput screen identifies disulfiram as a potential therapeutic for triple-negative breast cancer cells: Interaction with IQ motif-containing factors vol.12, pp.18, 2013, https://doi.org/10.4161/cc.26063
- Comparing Role of Two Chemotherapy Regimens, CMF and Anthracycline-Based, on Breast Cancer Survival in the Eastern Mediterranean Region and Asia by Multivariate Mixed Effects Models: a Meta-Analysis vol.16, pp.14, 2015, https://doi.org/10.7314/APJCP.2015.16.14.5655